Auto-generated from public data. Not the firm's stated position.
Norinnova Invest appears to focus on early-stage companies in health and nutrition, with recent portfolio activity suggesting a particular emphasis on omega-3 and biotech applications. Based on disclosed data, the firm deploys check sizes between €1.5M and €3.0M into pre-seed and seed stage ventures, with portfolio companies spanning marine-derived supplements, drug discovery, and specialized delivery mechanisms.
Generated 1 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Focus and check size from the firm's website. Website reachable as of Sept 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.